Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS inhibitor-naïve Chinese patients with KRAS-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies.
Dongde Wu, Zhiye Zhang, Xiangjiao Meng, Dong Hua, Zhiwu Wang, Cunji Wang, Huijuan Wang, Ying Yuan, Yi Hu, Xiaorong Dong, Xiaoyan Li, Mengna Huang, Kefeng Ding, Jingjing Huang, Lian Liu, Yongdong Jin, Zengqing Guo, Xiuwen Wang, Meili Sun, Mingjun Zhang, Mingfang Zhao, Yueyin Pan, Dingzhi Huang, Sheng Hu, Sujie Zhang, Yanhong Deng, Nong Yang
Signal transduction and targeted therapy 2025;10(1):241